- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
- Interventions
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Drug
- Lead sponsor
- Oncology Center of Biochemical Education And Research
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 239
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung, Non Small Cell Carcinoma of the Lung, Small Cell Carcinoma of the Lung
- Interventions
- Not listed
- Lead sponsor
- Pathway Genomics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Neoplasms, Breast
- Interventions
- Niraparib, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Burbank, California • Duarte, California • Palo Alto, California + 20 more
- Conditions
- Colorectal Cancer, Rectal Cancer
- Interventions
- Botensilimab, Balstilimab, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
- Interventions
- Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine, Vinorelbine, Liposomal Doxorubicin, Foresight CLARITY™ LDT, Pegfilgrastim, Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)
- Drug · Radiation · Device + 1 more
- Lead sponsor
- Michael Spinner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 6
- States / cities
- Davis, California • Fresno, California • Irvine, California + 3 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- MGCD265
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more
- Conditions
- Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases
- Interventions
- Data and Specimen Collection
- Genetic
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care, Circulating Tumor DNA test (ctDNA test)
- Other · Radiation · Diagnostic Test
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant, Tamoxifen, Palbociclib
- Drug
- Lead sponsor
- Shannon Puhalla
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Bile Duct Cancer
- Interventions
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
- Diagnostic Test
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Seattle, Washington
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Interventions
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Device · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pancreas Cancer, Pancreas Adenocarcinoma
- Interventions
- Capecitabine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Blood and Tissue Collection
- Diagnostic Test
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Sunitinib, Regorafenib
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Appendiceal Adenocarcinoma, Colorectal
- Interventions
- Circulating tumoral DNA directed neoadjuvant therapy arm
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Pembrolizumab, Epacadostat
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chordoma of Spine, Chordoma of Skull Base, Chordoma of Sacrum
- Interventions
- ctDNA
- Diagnostic Test
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Timeline
- 2024 – 2031
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
- Interventions
- CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
- Device · Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Adjuvant Therapy
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Malignant Digestive System Neoplasm, Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Minimal Residual Disease
- Interventions
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
- Biological
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- CXCR2 as a biomarker
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Observational
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pancreas Cancer
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 3
- States / cities
- DeKalb, Illinois • Geneva, Illinois • Warrenville, Illinois